# | Title | Journal | Year | Citations |
---|
1 | Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators | Anti-Cancer Drugs | 1996 | 729 |
2 | Drug-polymer conjugates | Anti-Cancer Drugs | 1992 | 435 |
3 | PI3K/Akt/mTOR pathway as a target for cancer therapy | Anti-Cancer Drugs | 2005 | 396 |
4 | Dendrimer-platinate | Anti-Cancer Drugs | 1999 | 394 |
5 | A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs | Anti-Cancer Drugs | 2009 | 358 |
6 | Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier | Anti-Cancer Drugs | 2007 | 343 |
7 | Triterpenoids as new promising anticancer drugs | Anti-Cancer Drugs | 2009 | 309 |
8 | Liposomal encapsulated anti-cancer drugs | Anti-Cancer Drugs | 2005 | 294 |
9 | Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines | Anti-Cancer Drugs | 1997 | 290 |
10 | Histone deacetylase inhibitors in cancer treatment | Anti-Cancer Drugs | 2002 | 280 |
11 | Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part I | Anti-Cancer Drugs | 1995 | 252 |
12 | Targeting Stat3 in cancer therapy | Anti-Cancer Drugs | 2005 | 252 |
13 | Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel | Anti-Cancer Drugs | 2001 | 246 |
14 | Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines | Anti-Cancer Drugs | 1996 | 239 |
15 | Preclinical characteristics of gemcitabine | Anti-Cancer Drugs | 1995 | 235 |
16 | NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent | Anti-Cancer Drugs | 2006 | 228 |
17 | Consequences of angiogenesis for tumor progression, metastasis and cancer therapy | Anti-Cancer Drugs | 1995 | 217 |
18 | Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study | Anti-Cancer Drugs | 2009 | 214 |
19 | Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers | Anti-Cancer Drugs | 1997 | 208 |
20 | Mitomycin C | Anti-Cancer Drugs | 1990 | 206 |
21 | Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assays | Anti-Cancer Drugs | 1995 | 202 |
22 | Pilot phase l-ll study on 5-aza-2??-deoxycytidine (Decitabine) in patients with metastatic lung cancer | Anti-Cancer Drugs | 1997 | 198 |
23 | Gemcitabine—a safety review | Anti-Cancer Drugs | 1998 | 186 |
24 | Enhancement of cytotoxicity by electropermeabilization | Anti-Cancer Drugs | 1998 | 185 |
25 | Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase–Akt/PKB survival pathway | Anti-Cancer Drugs | 2003 | 183 |
26 | EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism | Anti-Cancer Drugs | 2005 | 182 |
27 | Alternative drug formulations of docetaxel: a review | Anti-Cancer Drugs | 2007 | 181 |
28 | Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status | Anti-Cancer Drugs | 2008 | 181 |
29 | Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly | Anti-Cancer Drugs | 2003 | 180 |
30 | Non-viral vectors in cancer gene therapy: principles and progress | Anti-Cancer Drugs | 2001 | 176 |
31 | Sesquiterpene lactones as drugs with multiple targets in cancer treatment | Anti-Cancer Drugs | 2012 | 176 |
32 | COX-2 inhibitors in cancer treatment and prevention, a recent development | Anti-Cancer Drugs | 2002 | 169 |
33 | Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay | Anti-Cancer Drugs | 1996 | 167 |
34 | Betulinic acid, a natural compound with potent anticancer effects | Anti-Cancer Drugs | 2010 | 164 |
35 | The antioxidant caffeic acid phenethyl ester induces apoptosis associated with selective scavenging of hydrogen peroxide in human leukemic HL-60 cells | Anti-Cancer Drugs | 2001 | 162 |
36 | Molecular pathway for thymoquinone-induced cell-cycle arrest and apoptosis in neoplastic keratinocytes | Anti-Cancer Drugs | 2004 | 162 |
37 | Mechanism of action of rituximab | Anti-Cancer Drugs | 2002 | 161 |
38 | Programmed cell death (apoptosis) and response to anti-cancer drugs | Anti-Cancer Drugs | 1994 | 153 |
39 | Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities | Anti-Cancer Drugs | 2009 | 152 |
40 | Oral mucositis | Anti-Cancer Drugs | 2011 | 148 |
41 | Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review | Anti-Cancer Drugs | 2014 | 147 |
42 | Anti-tumor effect of gallic acid on LL-2 lung cancer cells transplanted in mice | Anti-Cancer Drugs | 2001 | 146 |
43 | Taxol | Anti-Cancer Drugs | 1991 | 141 |
44 | PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells | Anti-Cancer Drugs | 2009 | 141 |
45 | Autophagy and doxorubicin resistance in cancer | Anti-Cancer Drugs | 2018 | 136 |
46 | Toxicity of anticancer agents mediated by electroporation in vitro | Anti-Cancer Drugs | 2000 | 135 |
47 | Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines | Anti-Cancer Drugs | 1996 | 134 |
48 | Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models | Anti-Cancer Drugs | 2004 | 134 |
49 | Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects | Anti-Cancer Drugs | 2006 | 133 |
50 | Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer | Anti-Cancer Drugs | 2006 | 133 |